Stockreport

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio Inc. - Common stock  (INMB) 
PDF BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today anno [Read more]